Longevity Health (XAGE) Holdings announced the sale of 479,621 shares of its common stock at an average price of $4.08 per share through its at-the-market equity offering facility. Gross proceeds from the ATM sales totaled approximately $1.96M, prior to deducting fees and expenses. Assuming no growth beyond the Company’s pro forma consolidated FY24 sales and not factoring in the planned 20/20 merger, this financing extends XAGE’s cash runway into Q1 FY26.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XAGE:
- Longevity Health Gains Nasdaq Approval for Listing
- Longevity announces continued Nasdaq listing to complete 20/20 BioLabs deal
- Longevity Health reports unaudited Q1 revenue $663,000, up 8% year-over-year
- Longevity Health Holdings Inc trading halted, news pending
- Longevity Health Implements Reverse Stock Split